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Summary.-In view of the relatively poor prognosis for patients after surgery for
locally invasive colorectal cancer a trial of repeated systemic infusions of Coryne-
bacterium parvum (CP) has been carried out. It is in this group of patients, with a high
risk of recurrence from small residues of cancer left by the surgeon, that immuno-
therapy should have its optimum chance of success.
A total of 92 patients were included in a randomized controlled study. The two
groups were comparable in terms of tumour stage at presentation, operation per-
formed and mean age of patients, but the control group had a preponderance of male
patients. The study was carried out over 54 months. Treatment resulted in greater
side effects than had been predicted, and as a result many patients could not be
considered for inclusion.
IN 1977 CANCER ofthe colon and rectum
caused 16,462 deaths in England and
Wales (Office of Population Censuses and
Surveys, 1977). Advances in surgical
technique have not improved the pros-
pects of a cure for the patient presenting
with the disease. Surgical treatment in
the Oxford region (Gill & Morris, 1978)
gives results similar to those from
Birmingham (Slaney, 1971) and Bristol
(Walker, 1972). After excision of Dukes B
cancers, patients had an age-adjusted 5-
year survival rate of 58%, and for Dukes
C it was 27 1%. While specialized centres
of referral can report figures considerably
better than these (Whittaker & Goligher
1976; Lockhart-Mummery et al., 1.976), it
seems likely that our own results are more
representative of centres where a sub-
stantial proportion of cases of colorectal
cancer present as emergencies. These
results are particularly depressing when it
is considered how often the surgeon is
confident that he has removed all traces of
malignant tissue.
It is against this disappointing back-
ground that consideration has been given
to additional treatment after surgical
excision of these cancers (MacDonald,
1976; Carter 1976). One approach is
based on a postulated role for a specific
immune defence mechanism in the host
with colorectal cancer, with the concept
that this is depressed in these patients
and might be restored to normal by
appropriate immunostimulation. If a
specific defence mechanism did exist in
colorectal cancer (or in any cancer for
that matter), tumour-specific antigens
would be present and should be identi-
fiable. Conclusive proof for this, however,
is lacking.
Several in vitro and in vivo studies
support the view that tumour-specific
antigens are present in colorectal cancer,
and that they may evoke an immune
response in the tumour-bearing patient
(Gold & Freedman, 1965; Nairn et al.,
1971; Pihl et al., 1976; Vose et al., 1981;
Hollinshead et al., 1972; Bull et al., 1973;
Wanebo et al., 1980). Although the clinical
importance of these observations is not
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yet clear, it seems reasonable to assume
that the restoration of immune reactivity,
either specific or nonspecific, might in-
fluence the development and spread of
disease.
The anaerobic diphtheroid bacterium,
Corynebacterium parvum (CP) has been
extensively investigated in the treatment
of experimental animals bearing tumours
(Scott 1974 a, b). Its effect is probably
mediated by mononuclear phagocytes
when the bacterium is used systemically,
and CP treatment suppresses the develop-
ment of many transplantable tumours
(Scott, 1 974a). Early reports of the use of
CP in humans suffering from advanced
cancers suggested that the treatment was
well tolerated and led to prolonged
remission of disease in some patients
(Israel, 1975).
In view of the poor prognosis for
patients who present with Dukes B and C
colorectal cancers, this group was selected
for a trial of regular systemic infusions of
CP over the 2 years after surgical excision
of their tumours. Many relapses occur in
this period, and immune stimulation
might be expected to be of maximal
benefit when used in a patient bearing
minimal residual disease (Carter, 1976). It
was also of interest to see whether CP
treatment would influence the develop-
ment of distant metastases, since animal
experiments suggested that systemic use of
the bacterium would have a greater effect
in suppressing metastases than local
recurrence of tumour (Sadler & Castro,
1 976).
PATIENTS AND MATERIALS
Patients wN-ere considered for inclusion in the
trial during convalescence after surgery for
pathologically confirmed Dukes B and C
carcinoma of the colon or rectum. Dukes A
patientx Mwere excluded because of their
excellent prognosis. Patients -with advanced
disease and distant metastases wi-ere excluded
because of the improbability of immune
stimulation being effective against a large
bulk of residual disease.
Before randomization the side effects and
nature of the treatment -were explained to
all patients considered for inclusion in the
trial.
Treatment involved a series ofi.v. infusions
of CP in a dose of 5 mg/M2 given in a diluting
volume of 100 ml of normal saline over a
period of 30 min. The first treatment -was
-within a month of operation, and in each
patient it wa-as planned to give 10 infusions
in the 2 years after surgery. The treatment
interval was monthly for the first 3 infusions,
2-monthly for the next 3, and then in the
second year after surgery the last 4 w'ere
given 3-monthly. Treatment usually involved
an overnight stay in hospital, but some
patients were allowed home within 8 h of the
infusion. In our preliminary pilot study, and
from other reports, it -was evident that the
side-effects of i.v. CP included hypertension
and hypotension. In view of this, patients
who were known to suffer from cardiovascular
disease, hypertension or pulmonary disease
were not considered for treatment. Patients
with a history of allergy and those over the
age of 75 years -were also excluded.
The trial was carried out over a period of54
months. All patients randomized into the
trial have been followed up to the closing
date by the Consuiltant Surgeon wNho per-
formed the original operation. Thie diagnosis
of recurrence of disease -was based in general
on clinical criteria; no CEA estimations were
made.
Randomization was carried out according
to statistical tables supplied by the Depart-
ment of Medical Statistics, Oxford Univer-
sity. The statistical analyses of the survival
curves has been carried out by drawiing life
tables and applying the log-rank test (Peto
et al., 1977).
C. parvrum nwas provided as a generous gift
by Dr T. J. Priestman, Wellcome Research
Foundation, Beckenham, Kent.
RESULTS
A total of 44 patients were randomized
into the treatment group and 48 into the
control group (Table I). The average age
of the control patients was rather less
than that of the treatment group, being
58-9 years and 63-4 years respectively.
The sex distribution between the groups
was unequal: 38.6% (17/44) of the treat-
ment group were males compared with
66.60o (32148) in the control group.
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TABLE I. Analysis ofpatients entered into
the clinical trial
Total
Male
Female
Mean age (yr)
Treatment (ontrol
44 48
17 32
27 16
63.4 58.1)
Dukes B tumours were evenly distri-
buted between the two groups, but there
were more Dukes C lesions in the control
group (Table II).
TABLE II. Staqinq ofpatients3 in trial
Du)kes stage Treatment
35
9
CoItrol
31
17
It was planned to give 10 infusions of
CP, but it became apparent that in many
patients it would not be reasonable to
pursue this. Although it was anticipated
that tolerance to the side effects of CP
would increase after the first few infusions,
this only occurred in the minority of
patients, and in only 7 out of the 44
patients was the full course given. Over
half the group, however, received 5 or
more infusions. Eight patients rando-
mized to treatment received none. These
have been included in the analysis of the
figures as treatment patients.
Recurrence of cancer has occurred to
date in over 27%0 of the treatment
patients (12/44), and nearly 30o% (13/44)
ofthem are dead (Table III, Fig. 1). Three
of these deaths have been from causes
other than colorectal cancer; two patients
died from myocardial infarctions, one
during an apparently uneventful conva-
lescence and before receiving any CP;
TABLE III.-Fate of patients in trial
Treatment Control
D)eaths 13 12
Llecurrences 1 2 1I3
I)ead(l ue to recurreinee 10 11
D)ead from otlher cauises :3
5 years
1Fic. I ,ife-talble analysis of survival in tile two groujps. (...... control.
B
c
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the third patient died fromn a second
malignancy which developed in the uterus
and was histologically confirmed as unre-
lated to the colonic cancer.
Nine patients developed recurrent
cancer during the course of CP infusions.
Seven patients had the full course of 10
infusions, and only one of them has de-
veloped recurrence of disease. An almost
identical percentage of the control group
of patients has developed signs of re-
current cancer. Although the recurrence
rate is 27% (13/48) the percentage who
are dead is rather lower than in the
treatment group, being 25% (12/48). Only
one death in the control group was not due
to recurrent cancer, this patient dying
from acromegalic cardiomyopathy.
The mean intervals before recurrence
are virtually identical: 17-3 months in the
treatment group and 17 months in the
controls.
When the 36 patients who actually
received CP are considered, 10 have so far
died of recurrent cancer, the median
times to recurrence and death being 18 9
months and 28 months respectively. The
principal sites of recurrence were intra-
abdominal in both groups.
Of the 25 patients receiving 5 or more
infusions, 8 (32%) are dead, 7 from re-
current cancer. Nor did those patients
receiving prolonged treatment show any
difference in the sites of recurrence.
When life-table analysis was applied to
the survival figures according to the Dukes
stage there was still no difference between
the groups (Fig. 2).
Table IV shows the principal sites where
tumour recurrence first became evident.
TABLE IJV. Analysis of recurrences in
trial patients
Pirincipal sites of
recurrenee Treatmenit (onitrol
Local 2 3
Intra-ad)(lominal 9 9
Extra-abdominal I I
Dukes B
5 vear-
Fin(-. 2. -Life-table aiialysis of survival in the two groups a((or(ling to tuirnoit- stage at presentation.
(.... (ontrol. treatment).
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It does not appear that treatment has
influenced the pattern of recurrence. In
clinical practice it is often impossible to be
sure of the extent of recurrence of cancer,
and for the purpose of this trial the most
obvious sites of recurrence have been
assumed also to be the main sites. Most
of the recurrences in both groups have
been within the abdominal cavity. In a
few cases recurrence appeared to be
genuinely localized, for example at the
site of the anastomosis or involving
structures near the site of the original
tumour excision. Two patients in the
control group had second resections for
locally recurrent cancer, and both are
still alive 30 and 24 months from their
second operations.
1)ISCUSSION
There was no difference in survival or in
the incidence of recurrence between the
control and treatment groups in this
trial of adjutvant immunotherapy in
Dukes B and C colorectal cancer. However,
both the treatment and the control groups
of patients show better survival figures
than in the retrospective study on patients
presenting with colorectal cancer in Oxford
reported by Gill et al. (1977) and Gill &
Morris (1978). This is probably explained
by the selection of younger and relatively
healthy patients for inclusion in the trial.
The observation also emphasizes the
dangers in the use of historical controls.
The Oxford retrospective study also
showed that there were no significant sex
differences in prognosis after surgery. It
might be that the preponderance of male
patients in the control group of this study
has biased the results, because the overall
improvement in prognosis for female
patients has long been known (Gabriel,
1948).
The death of a patient who sustained a
myocardial infraction within 24 h of
treatment led to concern that the trial
should be stopped (Gill et al., 1977). This
patient had tolerated the first infusion
well, but during the second had a marked
hypotensive episode from which he ap-
peared to recover satisfactorily. Hlowever,
12 h later he developed crushing chest pain
and died with irrefutable evidence of an
acute myocardial infraction. Although no
further tragedies occurred after the adop-
tion of a more rigid exclusion policy, this
resulted in very low input to the trial,
with the exclusion of a high percentage
of otherwise suitable patients because of
concern about the side-effects of CP.
At the beginning of this trial it seemed
reasonable to aim for a course ofinfusions.
Unfortunately the tolerance which was
reported to build up after the first few
infusions (Israel, 1975) developed only in a
minority of our patients. Indeed, some
patients suffered from increasingly severe
side-effects. Most of the patients who did
not complete the course of treatment were
withdrawn by the investigating team, but
2 found the side-effects intolerable and
requested that treatment be stopped.
The 8 treatment-group patients who did
not receive CP comprised 1 lady who died
during convalescence, and 7 who declined
treatment having previously given in-
formed consent before randomization. As
a full discussion of the side-effects and
nature of the proposed treatment took
place before randomization, it is perhaps
understandable that these patients had
second thoughts about undergoing the
infusions once they were discharged from
hospital. No subsequent attempt was
made to persuade these patients to have
the treatment.
The poor outlook for Dukes B and C
colorectal cancer has prompted many
other clinical trials of adjuvant treatment
after surgery (Li & Ross, 1976; Valdivieso
& Mavligit, 1978). In several of these,
chemotherapy with 5-fluorouracil (FU)
has been used, and in other trials chemo-
therapy was combined with attempted
stimulation of the immune system (Mac-
Donald, 1976). The most commonly adop-
ted means ofimmune stimulation has been
repeated doses of BCG, usually adminis-
tered by scarification. As this treatment
was often very unpleasant, painful and
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sometimes caused local ulceration, frac-
tions of the BCG cell wall have also been
used, since these were thought to be less
likely to cause side-effects. The results
from most of these trials are inconclusive
or not yet published. Where claims of
benefit have been made (e.g. the M. D.
Anderson group), the structure of the trial
must be questioned (Valdivieso & Mavligit,
1978). In that trial patients were treated
after surgery for Dukes C cancers in two
ways. Some patients received repeated
scarification with BCG alone, while others
had the same treatment combined with
oral FU. BCG treatment involved scarifi-
cation weekly for 3 months, and then on
alternate weeks. FU treatment involved
150 mg/M2 ofthe drug taken orally 4 times
a day for 5 days, once every 4 weeks over
2 years. Each group had a prolonged
disease-free interval, and a survival curve
that matched that of a historical control
group of patients who had suffered from
Dukes B cancer. Since both treatment
groups had similar disease-free intervals
and survival times it seemed resaonable to
attribute this to the BCG rather than the
FU. However, these figures must be
criticized because of the use of a historical
control. The apparent improvement in the
outcome oftreatment for Dukes C patients
could well have been due to other factors,
for example a change in the type of
patient presenting for surgery. If the
survival ofthe control group with Dukes C
lesions is carefully considered in isolation,
it appears particularly poor and hence the
improvement in prognosis for both treat-
ment groups in this study may not be real.
Israel's report (1975) of the beneficial
effect of systemic CP in advanced human
malignancy engendered considerable en-
thusiasm for this approach. However,
confirmation of a beneficial effect of CP in
advanced cancer has not been provided
from other centres. (Fisher et al., 1976;
Chare et al., 1978).
The ability of a treatment to influence
the growth and spread of tumours in
laboratory animals supports the investi-
gation ofits use in human malignancy. But
laboratory results are not necessarily of
clinical relevance. Even in laboratory
animals, systemic CP has a weak action
against large tumour masses, and is more
effective in suppressing the development
of metastases (Sadler & Castro, 1976) CP
in our trial has not influenced the re-
currence of disease.
One objection to the use of immuno-
stimulants is the lack of specificity for
target cells, and the risk of suppressing
existing 8pecific defence mechanisms, e.g.,
increasing a population of suppressor T
cells, leading to enhanced tumour growth.
None of the early human studies with CP
in advanced human cancers suggested
that this did happen, but there was a clear
need for caution in monitoring the pro-
gress of the patients in our trial (Fisher,
1978; James et al., 1978).
The trial has now been closed. No
obvious beneficial or deleterious effect of
CP infusions was found in Dukes B or C
colorectal cancers, as determined by
patient survival, cancer recurrence and the
time of recurrence. However, the small
numbers studied do not allow us to
exclude the possibility of there being a
small effect, beneficial or deleterious,
which would only be apparent with many
more patients.
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Cancer Researclh Campaign.
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